Version May 2024
Note: Isoxsuprine has been discontinued in the United States for >1 year.
Cerebrovascular insufficiency: Oral: 10 to 20 mg 3 or 4 times daily.
Peripheral vascular disease: Oral: 10 to 20 mg 3 or 4 times daily.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
Avoid use (Ref).
The following adverse drug reactions are derived from product labeling unless otherwise specified.
Frequency not defined:
Cardiovascular: Chest pain, hypotension, tachycardia
Dermatologic: Skin rash (severe)
Gastrointestinal: Abdominal distress, nausea, vomiting
Nervous system: Dizziness
Arterial bleeding; use immediately postpartum
Concerns related to adverse effects:
• Rash: Severe rash has been reported; discontinue use if rash appears.
Isoxsuprine has been discontinued in the United States for >1 year.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Tablet, Oral, as hydrochloride:
Generic: 10 mg [DSC], 20 mg [DSC]
Yes
Tablets (Isoxsuprine HCl Oral)
10 mg (per each): $1.19
20 mg (per each): $0.80
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Cerebrovascular insufficiency: Relief of symptoms associated with cerebrovascular insufficiency.
Peripheral vascular diseases: Treatment of peripheral vascular diseases, such as arteriosclerosis obliterans, thromboangiitis obliterans (Buerger disease), and Raynaud disease.
Note: More appropriate therapies (medical or surgical) should be considered; efficacy of isoxsuprine in the treatment of these conditions has not been well established.
Vasodilan may be confused with Vasocidin
Beers Criteria: Isoxsuprine is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due lack of efficacy (Beers Criteria [AGS 2023]).
None known.
There are no known significant interactions.
Isoxsuprine crosses the placenta. Adverse effects (eg, hypocalcemia, hypoglycemia, hypotension, and ileus) requiring treatment have been observed in infants born to mothers who received isoxsuprine during pregnancy. Maternal and fetal tachycardia have occurred with use and pulmonary edema has been reported with maternal use of beta stimulants (Brazy 1979; Brazy 1981). Although isoxsuprine has been evaluated for the treatment of preterm labor, use for this indication is not currently recommended (ACOG 171 2016).
It is not known if isoxsuprine is excreted in breast milk.
Isoxsuprine increases muscle blood flow, but skin blood flow is usually unaffected. Rather than increasing muscle blood flow by beta-receptor stimulation, isoxsuprine probably has a direct action on vascular smooth muscle. The generally accepted mechanism of action of isoxsuprine on the uterus is beta-adrenergic stimulation (Kaindl 1959; Samuels 1959).
Absorption: Rapid and complete (Samuels 1959)
Time to peak, serum: ~1 hour; serum concentrations maintained for at least 3 hours (Kaindl 1959)
Excretion: Urine (Kaindl 1959)
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
